The global artificial tears market size is expected to reach USD 4.30 billion by 2028, exhibiting a CAGR of 5.9% during the forecast period. The growing incidence of ocular diseases can be a vital factor amplifying the growth of the global market, states Fortune Business Insights, in a report, titled “Artificial Tears Market Size, Share & COVID-19 Impact Analysis, By Type (Polyethylene Glycols (PEG) and Polypropylene Glycols (PPG), Cellulose, and Others), By Delivery (Eye Drops, and Ointments), By Application (Dry Eye Syndrome, Allergies & Infections, and Others), By Distribution Channel (Hospital Pharmacies, Drug Stores & Retail Pharmacies, and Online Pharmacies), and Regional Forecast, 2021-2028.” The market size stood at USD 2.64 billion in 2020.
Request for Free Sample Report PDF @ https://www.fortunebusinessinsights.com/enquiry/request-sample-pdf/artificial-tears-market-103486
The Report Lists the Main Companies in the Artificial Tears Market:
- Allergan (AbbVie Inc.) (Dublin, Ireland)
- Santen Pharmaceutical Co., Ltd. (Osaka, Japan)
- Bausch & Lomb (Laval, Canada)
- Alcon (Geneva, Switzerland)
- Novartis AG (Basel, Switzerland)
- Akorn Inc. (Lake Forest, U.S.)
- Eyevance Pharmaceuticals LLC (Forth Worth, U.S.)
- Sun Pharmaceutical Industries Ltd. (Mumbai, India)
- Johnson & Johnson (New Brunswick, U.S.)
- Bayer AG (Leverkusen, Germany)
- Otsuka Pharmaceutical Co., Ltd. (Tokyo, Japan)
- Other Players
Presence of Eminent Players to Promote Business in North America
The market size in North America stood at USD 1.38 billion in 2019. The growth in North America is attributed to the robust healthcare infrastructure. The growing demand for sophisticated artificial tears will enable the growth of the market. The presence of key market players will influence growth in the region. The increasing prevalence of dry eye syndrome and other ocular diseases such as eye allergies will create lucrative business opportunities for the market. As per the survey conducted by National Health and Wellness in 2013, it was estimated that up to 6.8% of the population in the U.S. was to be affected by dry eye syndrome. The large patient population is likely to accelerate revenue in North America. The market in Asia Pacific is expected to witness a rapid growth rate during the forecast period due to the growing awareness about ocular diseases. The increasing patient population and healthcare expenditure will foster the healthy growth of the market in the region. The Middle and East and Africa are predicted to account for a significant share in the global market due to the enriching economic conditions and improved healthcare systems.
October 2019: Allergan released a new product line called Refresh Relieva lubricant eye. The launch of the novel product will help the company retain its position in the eye drop industry.
Ask for Customization @ https://www.fortunebusinessinsights.com/enquiry/customization/artificial-tears-market-103486
List of Key Players Covered in this Market Report:
- MD (CA, USA)
- PENTAX Medical (Tokyo, Japan)
- Richard Wolf GmbH. (Illinois, United States)
- Stryker (Michigan, United States)
- Elmed Electronics & Medical Industry & Trade Inc. (Ankara, Turkey)
- KARL STORZ (Tuttlingen, Germany)
- Olympus Corporation (Tokyo, Japan)
Continued. . .
NOTE: Our team is studying Covid19 and its impact on various industry verticals and wherever required we will be considering covid19 footprints for a better analysis of markets and industries. Cordially get in touch for more details.
Fortune Business Insights™ delivers accurate data and innovative corporate analysis, helping organizations of all sizes make appropriate decisions. We tailor novel solutions for our clients, assisting them to address various challenges distinct to their businesses. We aim to empower them with holistic market intelligence, providing a granular overview of the market they are operating in.
Fortune Business Insights™ Pvt. Ltd.
308, Supreme Headquarters,
Survey No. 36, Baner,
Pune – 411045, Maharashtra, India.
US :+1 424 253 0390
UK : +44 2071 939123
APAC : +91 744 740 1245